INFLUENCE OF MOLECULAR-WEIGHT ON PASSIVE TUMOR ACCUMULATION OF A SOLUBLE MACROMOLECULAR DRUG CARRIER

被引:292
作者
SEYMOUR, LW
MIYAMOTO, Y
MAEDA, H
BRERETON, M
STROHALM, J
ULBRICH, K
DUNCAN, R
机构
[1] UNIV KEELE, DEPT BIOL SCI, CANC RES CAMPAIGN, POLYMER CONTROLLED DRUG DELIVERY GRP, KEELE ST5 5BG, STAFFS, ENGLAND
[2] KUMAMOTO UNIV, SCH MED, DEPT MICROBIOL, KUMAMOTO 860, JAPAN
[3] ACAD SCI CZECH REPUBL, INST MACROMOLEC CHEM, PRAGUE 6, CZECH REPUBLIC
[4] UNIV BIRMINGHAM, BIRMINGHAM INST CANC STUDIES, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND
关键词
POLYMER CONJUGATES; TARGETING; N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMERS; VASCULAR PERMEABILITY;
D O I
10.1016/0959-8049(94)00514-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The molecular weight-dependence of tumour capture of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers (fractions of mw 22000-778000) was studied in vivo using subcutaneous (s.c.) Sarcoma 180 or B16F10 melanoma models. At 10 min, all fractions were already detectable in the tumour (1.5-3% of dose administered per gram) and those of molecular weight greater than the renal threshold showed progressive tumour accumulation up to 20% of dose administered per gram after 72 h in the Sarcoma 180 model. Tumour-selective uptake was confirmed for all copolymer fractions in both tumour models and in the sarcoma 180 model, the ratio (accumulation index, AI) of the AUC in tumour to AUC in skeletal muscle (a typical normal tissue) increasing from six to 12 with increasing copolymer molecular weight. The tumour/blood Al was greater (1-3) in the Sarcoma 180 model than the B16F10 melanoma model (O.4-1.0).
引用
收藏
页码:766 / 770
页数:5
相关论文
共 29 条
  • [11] AUGMENTATION OF TUMOR DELIVERY OF MACROMOLECULAR DRUGS WITH REDUCED BONE-MARROW DELIVERY BY ELEVATING BLOOD-PRESSURE
    LI, CJ
    MIYAMOTO, Y
    KOJIMA, Y
    MAEDA, H
    [J]. BRITISH JOURNAL OF CANCER, 1993, 67 (05) : 975 - 980
  • [12] MAEDA H, 1989, CRIT REV THER DRUG, V6, P193
  • [13] MAEDA H, 1992, J CONTROL RELEASE, V19, P315, DOI 10.1016/0168-3659(92)90086-7
  • [14] SMANCS AND POLYMER-CONJUGATED MACROMOLECULAR DRUGS - ADVANTAGES IN CANCER-CHEMOTHERAPY
    MAEDA, H
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1991, 6 (02) : 181 - 202
  • [15] TAILOR-MAKING OF PROTEIN DRUGS BY POLYMER CONJUGATION FOR TUMOR TARGETING - A BRIEF REVIEW ON SMANCS
    MAEDA, H
    MATSUMOTO, T
    KONNO, T
    IWAI, K
    UEDA, M
    [J]. JOURNAL OF PROTEIN CHEMISTRY, 1984, 3 (02): : 181 - 193
  • [16] MAEDA H, 1979, INT J PEPT PROT RES, V14, P81
  • [17] CONJUGATES OF ANTICANCER AGENTS AND POLYMERS - ADVANTAGES OF MACROMOLECULAR THERAPEUTICS INVIVO
    MAEDA, H
    SEYMOUR, LW
    MIYAMOTO, Y
    [J]. BIOCONJUGATE CHEMISTRY, 1992, 3 (05) : 351 - 362
  • [18] MATSUMURA Y, 1986, CANCER RES, V46, P6387
  • [19] MIJNHEERE EP, 1991, BRIT J CANCER, V63, P78
  • [20] THE THERAPEUTIC VALUE OF POLY(ETHYLENE GLYCOL)-MODIFIED PROTEINS
    NUCCI, ML
    SHORR, R
    ABUCHOWSKI, A
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1991, 6 (02) : 133 - 151